ZVRA
ZEVRA THERAPEUTICS, INC.
Next earnings Aug 10, 2026 · consensus $0.10 EPS, $34.7M rev
Last earnings +6.0% on 2026-05-06
$13.52
▲ +2.19%$13.52▲ +50.22%
over 1Y
L $7.23EODHDH $13.66
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.2%
1W+6.9%
1M+23.5%
3M+47.6%
YTD+62.1%
1Y+50.2%
Hold
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 15 analysts
Buy
MIPLYFFA launch + one-time $148M PRV sale flipped Zevra to profit, but operating loss persists — own it, don't chase it.
Revenue $106M · FY2025
The read
Middling fundamentals offset by an attractive price (~279% below fair value) — worth a look on the value angle.
Zevra's FY2025 results look transformative on the surface: revenue jumped 350.9% to $106M and net income swung to +$83.2M from -$106M, driving a headline P/E of 9.9x. But the MD&A makes clear the profit is not operational — the company sold its rare pediatric disease priority review voucher (PRV) on April 1, 2025 for $148.3M in net proceeds, which mechanically converts a money-losing commercial-stage biotech into a 'profitable' one for a single year. Strip that out and operating income remains -$62.9M (operating margin -59.1%), and operating cash flow is still -$1.6M despite the cash windfall. The 78.2% net margin and 53.8% ROE are accounting artifacts, not durable economics.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $28.6M | $10.2M | $27.5M | $23.6M | $106M |
| Gross profit | — | — | — | — | — |
| Operating income | $7.73M | -$42.6M | -$49.6M | -$87.0M | -$62.9M |
| Net income | -$8.55M | -$26.8M | -$46.0M | -$106M | $83.2M |
| Diluted EPS | -$2.11 | — | — | -$2.28 | $1.35 |
| Net margin | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$793M
EV / EBITDA—
EV / Sales7.5
EV / FCF—
P / FCF—
PEG (trailing)0.06
Earnings yield10.5%
FCF yield-0.3%
Quality & risk
ROIC (est.)-23.0%
Free cash flow-$2.43M
Total debt$61.9M
Net cash$478K
Altman Z-Score2.01 grey
Piotroski F-Score5/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+8.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Shareholder vote2026-06-05
Annual meeting vote results disclosed; routine director/auditor ratifications.
- 8-K Earnings results2026-05-06
Q1 2026 10-Q: MIPLYFFA commercial traction, cash $62M after PRV proceeds.
- 10-Q Quarterly report2026-05-06
Q1 2026 10-Q: MIPLYFFA commercial traction, cash $62M after PRV proceeds.
- DEF 14A Proxy statement2026-04-20
DEF 14A proxy: director slate, comp and auditor ratification for annual meeting.
- 8-K Agreement terminated2026-03-16
Entered new material agreement and terminated another; pipeline/partnership reshuffle.
- 8-K Officer / director change2026-03-09
FY25 10-K: first profitable year, $148M PRV sale, MIPLYFFA launch, EU MAA filed.
- 10-K Annual report2026-03-09
FY25 10-K: first profitable year, $148M PRV sale, MIPLYFFA launch, EU MAA filed.
- 8-K Officer / director change2025-12-17
Executive officer change disclosed; management transition.
- 8-K Officer / director change2025-12-02
Officer departure/appointment plus Reg FD update; leadership reshuffle.
Recent filings
all on EDGAR ↗4Period ending 2026-06-212026-06-23open ↗4Period ending 2026-06-042026-06-18open ↗4Period ending 2026-06-042026-06-18open ↗4Period ending 2026-06-042026-06-18open ↗4Period ending 2026-06-042026-06-18open ↗4Period ending 2026-06-042026-06-18open ↗4Period ending 2026-06-042026-06-18open ↗8-KPeriod ending 2026-06-042026-06-05open ↗4Period ending 2026-05-282026-05-29open ↗4Period ending 2026-05-112026-05-13open ↗144Filing2026-05-11open ↗10-QPeriod ending 2026-03-312026-05-06open ↗
Frequently asked
- Is ZEVRA THERAPEUTICS, INC. (ZVRA) a buy?
- ZVRA currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. MIPLYFFA launch + one-time $148M PRV sale flipped Zevra to profit, but operating loss persists — own it, don't chase it.
- What is ZVRA's fair value?
- A Modified-Graham model based on ZVRA's SEC fundamentals estimates a fair value of about $51.30. It is an estimate from reported earnings, not a price target.
- Is ZVRA overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, ZVRA currently appears undervalued relative to its SEC-grounded earnings power.
- What is ZEVRA THERAPEUTICS, INC.'s quality score?
- ZVRA scores 78.27450980392156/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001434647, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/25/2026, 3:04:50 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.